Insulin Glargine is used for: Diabetes mellitus.
Recorded in the NepalDoc medicine catalog for Insulin Glargine.
BASAGLAR ® is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.
From the U.S. FDA-approved label for Insulin Glargine. Full label: DailyMed.
BASAGLAR ® is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.
From the U.S. FDA-approved label for Insulin Glargine. Full label: DailyMed.
Individualize dosage based on metabolic needs, blood glucose monitoring, glycemic control, type of diabetes, prior insulin use. Administer subcutaneously once daily at any time of day, but at the same time every day. Rotate injection sites into the abdominal area, thigh, or deltoid to reduce the risk of lipodystrophy and localized cutaneous amyloidosis.
Directions from the U.S. FDA-approved label for Insulin Glargine — your doctor or pharmacist may advise differently.
BASAGLAR is contraindicated: During episodes of hypoglycemia. In patients with hypersensitivity to insulin glargine or any of the excipients in BASAGLAR. During episodes of hypoglycemia. Hypersensitivity to BASAGLAR or any of its excipients.
Excerpt from the U.S. FDA-approved label for Insulin Glargine. Talk to a pharmacist or doctor before use.
Never share a BASAGLAR prefilled pen between patients, even if the needle is changed. Hyperglycemia or hypoglycemia with changes in insulin regimen: Make changes to a patient's insulin regimen (e.g., insulin strength, manufacturer, type, injection site or method of administration) under close medical supervision with increased frequency of blood glucose monitoring. Hypoglycemia: May be life-threatening.
Warnings and precautions excerpt from the U.S. FDA-approved label for Insulin Glargine — not a complete list. Talk to a pharmacist or doctor before use.
The following adverse reactions are discussed elsewhere: Hypoglycemia. Hypoglycemia Due to Medication Errors. Hypersensitivity Reactions. Hypokalemia. Adverse reactions commonly (≥5%) associated with insulin glargine products are: Hypoglycemia, allergic reactions, injection site reaction, lipodystrophy, pruritus, rash, edema, and weight gain.
Excerpt from the U.S. FDA-approved label for Insulin Glargine — not a complete list. Talk to a pharmacist or doctor about side effects.
6 brands · 3 makers in the NepalDoc catalog — see the full Insulin Glargine guide →
16.2 Storage and Handling Dispense in the original sealed carton with the enclosed Instructions for Use. Protect BASAGLAR from heat and light. Do not freeze BASAGLAR. In-use BASAGLAR prefilled pens must be used within 28 days or be discarded, even if they still contain BASAGLAR.
Storage information from the U.S. FDA-approved label for Insulin Glargine.
What is Lantus U 100?
Lantus U 100 Vial is a Insulin Glargine medicine made by Aventis Pharma Limited. It comes as Vial.
What is Lantus U 100 used for?
Insulin Glargine is used for Diabetes mellitus.
What is the generic name of Lantus U 100?
The generic name of Lantus U 100 is Insulin Glargine.
Which brands of Insulin Glargine are available in Nepal?
6 brands of Insulin Glargine are listed in the NepalDoc catalog, from 3 makers — including Glaritus Injection, Lantus Injection, Lantus 100IU Cartridge, Lantus Solostar 100IU Pen, Lantus Starter Vial.
What are the side effects of Insulin Glargine?
The following adverse reactions are discussed elsewhere: Hypoglycemia. Hypoglycemia Due to Medication Errors. Hypersensitivity Reactions. Hypokalemia.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. A catalog listing does not guarantee that a medicine is in stock at any pharmacy.
